

COMPANY ANNOUNCEMENT

MEDSERVREGIS P.L.C.
(THE “COMPANY”)

**Issue of up to the Euro equivalent of €25,000,000 in EUR and USD unsecured Bonds
due 2031 – 2036
Basis of Acceptance**

Date of Announcement	25 November 2025
Reference	337/2025
Capital Markets Rule	CMR 5.16.12

Quote

The Company is pleased to announce the basis of acceptance in respect of the issue by the Company (hereinafter, the “**Bond Issue**”) of up to the Euro equivalent of €25,000,000 in EUR and USD unsecured bonds due 2031 – 2036 (hereinafter, the “**New Bonds**”) in terms of a prospectus issued by the Company and dated 20 October 2025 (hereinafter, the “**Prospectus**”).

As set out in the Prospectus, the proceeds from the Bond Issue will be used by the Company towards the cancellation of a combination of 5.75% USD unsecured bonds (ISIN: MT0000311242) (hereinafter, the “**USD Bonds**”) and 4.5% EURO unsecured bonds (ISIN: MT0000311234) (hereinafter, the “**EURO Bonds**”, which together with the USD Bonds shall hereinafter be referred to as the “**2015 Bonds**”) issued pursuant to a prospectus dated 21 December 2015.

Pursuant to the terms and conditions set out in the Prospectus, the New Bonds were made available for subscription by holders of the 2015 Bonds (hereinafter, the “**Existing Bondholders**”) by means of an exchange offer. Under this offer, Existing Bondholders had the option of surrendering the 2015 Bonds held by them in favour of the Company in exchange for New Bonds of the same currency (EUR or USD, as applicable), equivalent in value to the New Bonds applied for (hereinafter, the “**Exchangeable Bonds Transfer**”). Any New Bonds not subscribed for by Existing Bondholders as aforesaid were available for subscription through an intermediaries’ offer (hereinafter, an “**Intermediaries’ Offer**”). Reference is made to the company announcement issued by the Company on 7 November 2025 (335/2025) whereby the Company, *inter alia*, announced its decision to: (i) extend the issue period during which Exchangeable Bonds Transfers may be effected to 13:00 CET on 20 November 2025 (hereinafter, the “**Closing Date**”); and (ii) launch the Intermediaries’ Offer until the Closing Date.

As at the Closing Date, the Company received a total of 85 applications from Existing Bondholders for a total value of €13,185,000 and \$5,735,000, respectively. The Company will allocate the full amount subscribed for by Existing Bondholders.

MedservRegis p.l.c.

MedservRegis p.l.c.
Port of Marsaxlokk
Birzebbugia, BBG 3011
Malta

T +356 2220 2000
E info@medservregis.com

W www.medservregis.com
Company registration No: C28847


Pursuant to the Intermediaries' Offer and as at the Closing Date, the Company received a total of €3,855,000 and \$165,000 from subscription agreements entered into between authorised financial intermediaries and the Company. The Company will allocate the full amount subscribed for by authorised financial intermediaries pursuant to the Intermediaries Offer.

In accordance with the company announcement issued by the Company on 7 November 2025 (335/2025), the New Bonds are expected to be admitted to listing on the Official List of the Malta Stock Exchange on 3 December 2025, and trading is expected to commence on 4 December 2025. Interest on the New Bonds will commence to accrue as from 3 December 2025. The suspension of trading of the 2015 Bonds on the Official List of the Malta Stock Exchange shall be lifted with effect from the close of business on the 3 December 2025, with trading in the 2015 Bonds to resume as from the 4 December 2025.

As set out in the Prospectus, any balance of 2015 Bonds not exchanged for New Bonds by the Closing Date shall be redeemed by the Company on 5 February 2026 (the redemption date of the 2015 Bonds), unless previously purchased by the Company by means of a buy-back programme (of a maximum amount of €4,000,000), if launched.

The Company welcomes the support demonstrated by both existing and new investors and is confident that the combination of the reduction in long-term debt as a result of the Bond Issue and the MedservRegis Group's continued strong cash-flow generation will further strengthen its capital structure and underpin its strategy.

Unquote



Nicola Jaccarini
Company Secretary